The Global Anti-Addiction Market, 2008-2023

March 19, 2009 - PRLog -- Report Details
The global addiction market is significantly undervalued. The world’s population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward. It covers the major therapy areas of smoking cessation, obesity, drug addiction and alcohol dependency. In addition, this study forecasts how your market will grow and develop, both quantitatively and qualitatively, during the period 2008-2023.

The Global Anti-Addiction Market, 2008-2023, uses a variety of primary and secondary research methods, including:
• Exclusive visiongain interviews with key opinion leaders in the addiction industry
• Examination of a wealth of secondary sources, including company reports, filings, analyst presentations and press releases
• Use of in-house and commercial sales databases.

Addiction rates are increasing, yet there is a relative lack of widely-efficacious drugs. Also, relatively few patients are treated and patient compliance is low for those who are treated at present. Nevertheless, the growth potential market of this market is significant, both in developed and developing countries. In addition, awareness of the human and healthcare costs associated with addiction is increasing amongst patients, healthcare practitioners and legislators. There is a sense of urgency to combat tobacco addiction, alcoholism and obesity in particular. Consequently, there are marked opportunities for companies marketing and developing anti-addiction drugs. But by how much will the market grow and which therapy areas will be the fastest growing? This report answers those questions and more besides.

Visiongain has applied detailed financial forecasting and analysis of market/industry drivers and restraints, including SWOT analysis. The resulting comprehensive market-based report reveals how leading addiction brands, therapy areas and markets will fare during the period 2008 to 2023. Key features of the addiction drugs of the future and the hurdles they will have to overcome for commercial success are discussed.

Other highlights of The Global Anti-Addiction Market, 2008-2023 report include:
• Expert opinion from representatives in the anti-addiction drug industry
• Sales forecasts for the global addiction market and for individual obesity, smoking cessation, drug addiction and alcohol addiction markets, including leading brands, manufacturers and country markets
• Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-addiction drugs market
• In-depth analysis of the anti-addiction pipeline
• Geographical breakdown of the anti-addiction drugs market
• Analysis of the addiction markets in the US, France and the UK.

Why you should buy this report:
• To receive a comprehensive analysis of the prospects for anti-addiction drugs, including key metrics and predicted revenues, by type of addiction and brand
• To receive forecasts of addiction drug sales, from 2008-2023, in leading country markets, including China and Mexico
• To read the views of experts in the addiction industry, regarding current and future trends, opportunities and sales drivers; the report includes full transcripts of interviews
• The report is packed with graphs, charts, figure and tables of analysis and sales forecasts
• To determine the forces that influence the market for anti-addiction drugs: drivers, restraints, opportunities and competitive factors
• To find out where the addiction market is heading - both technologically and commercially from 2008 onwards.

The information contained in this report is not available in any other source and is essential reading for you and your colleagues. By ordering and reading this report you can gain market advantage on your competitors today. When aligned with your in-house findings we are confident you will continue to succeed over the next 15 years.

Companies Listed
Abbott Laboratories
Actavis
Alizyme
Alkermes
Amylin
Arena
AstraZeneca
Barr
Biotie Therapies (Finland)
Biovail
Bristol-Myers Squibb
Celtic Pharma
Cephalon
CV Therapeutics
Cytos Biotechnology
Drake University (US)
Eisai
Elbion NV
Eli Lilly
European Medicines Agency (EMEA)
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Evotec
Food and Drug Administration (FDA)
Forest
GSK
Independent Pharmaceutica
Indevus
Johnson & Johnson
Karolinska Institutet (Sweden)
Lundbeck
Medley (Brazil)
Merck & Co.
Merck KGaA
Nabi Biopharmaceuticals
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute on Drug Abuse (NIDA, USA)
National Institutes of Health (NIH, USA)
Novartis
Novo Nordisk
OBEcure
Orexigen
Pfizer
Reckitt Benckiser
Roche
Rottapharm (Italy)
Sanofi-Aventis
Schering-Plough
Solvay
Somaxon
Synosia Therapeutics
Takeda
Titan
Vivant
WEX Pharmaceuticals
World Health Organization (WHO)
Xytis
Yaupon Therapeutics

Visiongain ltd.
4th Floor,
BSG House,
226-236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=364
Or http://www.visiongain.com

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.